Renalytix — TickStock

Renalytix AI plc is a clinical diagnostics company that develops artificial intelligence-powered blood tests for kidney disease detection and monitoring. The company operates primarily in the United States and United Kingdom, serving nephrology and primary care markets with its KidneyIntelX platform. As a small-cap AIM-listed company, Renalytix is in the commercialization phase, focusing on expanding adoption of its AI-driven diagnostic solutions in chronic kidney disease management.

Sector: Software & SaaS
Market: AIM

Identifiers

Ticker: AIM:RENX
Market: AIM
ISIN: GB00BYWL4Y04
LEI: 213800NTOH3FK3WER551

Learn more on:

GLEIF Companies House

Timeline

Renalytix expands testing capacity 3.5x and submits CE technical file for kidneyintelX.dkd

More in Software & SaaS

Polar Capital Technology Trust nearly doubles NAV

Cordel Group clears NSIA hurdle in Vossloh takeover

Tech Today: Computacenter profit doubles and guidance upgraded, GlobalData, Bango, Bytes Technology Group

Bango's cash earnings surpasses last year's total in six months

GlobalData launches share tender as underlying growth holds at 1%

Bytes Technology Group starts new financial year with growth

Small Caps Today: Capita profit warning hits outsourcer hard, Grit Investment Trust, Amcomri, Kazera Global, Bango, TruFin . . .

RC365 secures $2m credit facility

Computacenter upgrades guidance as first-half profit doubles

Boku cuts full-year guidance after carrier billing suspensions and slower merchant onboarding

Quartix Technologies lifts H1 revenue

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer